Atlas
Market PulseSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › GLAND

GLAND

Gland Pharma Limited
Small-capPharma ↗

What the six lenses say about GLAND — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹2469.5
2026-07-10
VWAP · 1Y anchor
₹2067
+19.5% from VWAP
P/E · TTM
39.6×
TTM EPS ₹62.4
52-week range
92%
position low→high
RSI(14)
63
momentum

Own sector index

Pharma ↗
Overweight

1M

+6.2%

3M

+15.8%

1Y

+16.2%

Breadth >EMA21

72%

How GLAND’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
7.5
avg conviction decile
Leadership
0/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Small-cap cohortDRaw
TechnicalD995›

The actual numbers

Price vs VWAP (1y)+19.5%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+26.8%
Price vs 50-EMA+11.0%
RSI(14)63
RS vs Nifty 500 · 3M+38.5%
RS vs sector · 3M+26.0%
52-week range92%
Volume vs 30d avg0.45×
Volume vs 60d avg0.50×
ATR(14) · volatility86.0
Bollinger width · vol contraction0.213
FundamentalD865›

The actual numbers

Return on equity (ROE)10.7%
Return on capital (ROCE)15.1%
Operating margin23.3%
Net margin16.0%
Revenue growth · YoY+14.5%
EPS growth · YoY+47.1%
Debt / equity0.03×

Full 8-quarter history in the financials table below.

ValuationD420›

The actual numbers

P/E (TTM)39.6×
TTM EPS₹62.4
52-week range92%
CatalystD640›

The actual numbers

Earnings & momentum41
Capital actions8
Governance118

Every filing in the corporate-announcements panel below.

FlowD650›

The actual numbers

Promoter holding51.8%
Delivery · 30d avg51.3%
Up/down-day asymmetry1.2pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D9 + D6 ) ÷ 2 = 7.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
91
Conviction score 91/100 · avg-decile strength 7.5/10
Conviction score91/100›
TechnicalD9›
FundamentalD8›
ValuationD4›
CatalystD6›
FlowD6›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-1.4pp
+1.8pp
+5.7pp
+42.1pp
+53.6pp
+39.4pp
Nifty 500
Broad-market baseline
-1.8pp
+1.7pp
+5.1pp
+38.5pp
+48.6pp
+35.6pp
Sector
Own-sector index
—
—
+2.7pp
+26.0pp
+34.2pp
+17.7pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

GLAND daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
2469.50-26.30

Relative strength

RS vs baseline · rebased to 100

GLAND ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
123.98-2.27

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)1,4021,4061,3841,4251,5061,4871,6951,743
↳ change QoQ—+0.3%-1.5%+3.0%+5.7%-1.3%+14.0%+2.8%
EBITDA (₹cr)316357418348368314435513
EBITDA margin22.5%25.4%30.2%24.4%24.4%21.1%25.7%29.4%
PAT (₹cr)144164205187215184261367
↳ change QoQ—+13.8%+25.2%-8.6%+15.0%-14.4%+41.8%+40.6%
Net margin10.3%11.6%14.8%13.1%14.3%12.4%15.4%21.1%
EPS (₹)8.739.9312.4211.3213.0811.1515.8722.26
D/E————————
YoY growth · Mar '26Revenue +22.3% YoYPAT +96.3% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 17 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 16 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 16 Jun '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 15 Jun '26
    MEDIUMgovernance
    Resignation of Director/KMP/SMP
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 15 Jun '26
    MEDIUMgovernance
    Change in Director(s)
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 15 Jun '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 4 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 2 Jun '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 20 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 18 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 15 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 15 May '26
    LOWgovernance
    Options to purchase securities
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 15 May '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds GLAND

Mutual funds holding GLAND (10)

FundWeightAUM ₹crGrade
HDFC Mid Cap Gr1.46%97,350
Nippon India Small Cap Dir Bns0.58%78,407
Nippon India Small Cap Gr Bns0.58%78,407
Nippon India Small Cap Gr0.58%78,407
Nippon India Multi Cap Gr0.55%54,585
Nippon India Multi Cap Dir Bns0.55%54,585
Nippon India Multi Cap Bns0.55%54,585
Nippon India Growth Md Cp Reg Gr PlGrOpt1.42%49,169
Nippon India Growth Mid Cap Dir Bns1.42%49,169
Nippon India Growth Md Cp Reg Gr Bns1.42%49,169

ETFs holding GLAND (10)

ETFWeightGrade
Nippon India Nifty Pharma ETF2.15%
Motilal Oswal BSE Select IPO ETF1.67%
Zerodha Nifty Smallcap 100 ETF1.64%
Mirae Asset Nifty 500 Healthcare ETF1.42%
Motilal Oswal BSE Healthcare ETF1.21%
HDFC Nifty Smallcap 250 ETF0.88%
Motilal Oswal Nifty Smallcap 250 ETF0.88%
Mirae Asset Nifty Smallcap 250 ETF0.88%
DSP Nifty Smallcap 250 ETF0.88%
Groww Nifty Smallcap 250 ETF0.88%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma